Recurrent hepatitis C after liver transplantation

Research output: Contribution to journalArticle

Abstract

Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (

Original languageEnglish
Pages (from-to)34-40
Number of pages7
JournalAnti-Infective Agents
Volume10
Issue number1
StatePublished - 2012
Externally publishedYes

Fingerprint

Hepatitis C
Liver Transplantation
Fibrosis
Ribavirin
Liver
Interferons
Transplantation
Genotype
Population
Therapeutics

All Science Journal Classification (ASJC) codes

  • Infectious Diseases
  • Pharmacology

Cite this

Recurrent hepatitis C after liver transplantation. / Mukherjee, Sandeep.

In: Anti-Infective Agents, Vol. 10, No. 1, 2012, p. 34-40.

Research output: Contribution to journalArticle

@article{be0c616b42744eb4853bec4687e123f9,
title = "Recurrent hepatitis C after liver transplantation",
abstract = "Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30{\%} of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42{\%} per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (",
author = "Sandeep Mukherjee",
year = "2012",
language = "English",
volume = "10",
pages = "34--40",
journal = "Anti-Infective Agents",
issn = "2211-3525",
publisher = "Bentham Science Publishers",
number = "1",

}

TY - JOUR

T1 - Recurrent hepatitis C after liver transplantation

AU - Mukherjee, Sandeep

PY - 2012

Y1 - 2012

N2 - Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (

AB - Recurrent HCV is universal after liver transplantation in patients viremic at the time of transplantation and leads to cirrhosis in up to 30% of patients by five years. Once cirrhosis develops, the risk of hepatic decompensation is 42% per year. This has led to recurrent HCV emerging as an important yet controversial indication for liver retransplantation and a renewed interest in the role of anti-viral therapies. Despite encouraging results with pegylated interferon and ribavirin in the non-transplant HCV population, these findings have not translated to transplant recipients where viral eradication is frequently unsuccessful for genotype 1 patients (

UR - http://www.scopus.com/inward/record.url?scp=84867509853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867509853&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 34

EP - 40

JO - Anti-Infective Agents

JF - Anti-Infective Agents

SN - 2211-3525

IS - 1

ER -